PERSPECTA

News from every angle

← Back to headlines

Merck's Cholesterol Drug Meets Main Goal in Head-to-Head Trial

A late-stage trial of a new Merck drug demonstrated a reduction in bad cholesterol by up to 64.6%, meeting its main goal in a head-to-head trial.

30 Mar, 16:09 — 30 Mar, 16:09
PostShare

Sources

Showing 1 of 2 sources
YahooMostly Factual149d ago

Merck's drug reduced bad cholesterol by up to 64.6% in late-stage trial

Read full article →

Coverage Timeline

First report: Yahoo · 30 Mar, 16:09Full coverage: 2 · 4hWindow: 4h
Left-leaningCenterRight-leaning
Yahoo30 Mar, 16:09First to report

Merck's drug reduced bad cholesterol by up to 64.6% in late-stage trial

4h later
Reuters30 Mar, 19:42Latest update

Merck's cholesterol drug meets main goal in head-to-head trial - Reuters

Related Stories

Busy Philipps Reveals She Underwent Surgery to Remove Rare Brain Tumor

42m ago

Closing Arguments Set as Murder Trial of Chris Benoit Nears Conclusion

47m ago

Eight-Year-Old Boy Dies After Electric Shock From Water Cooler in UAE

51m ago

FDA Grants Expedited Approval to Landmark Pancreatic Cancer Drug

1h ago